SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-237729
Filing Date
2021-08-05
Accepted
2021-08-05 16:17:04
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d212533d8k.htm   iXBRL 8-K 23482
2 EX-99.1 d212533dex991.htm EX-99.1 113406
6 GRAPHIC g212533g0805110817324.jpg GRAPHIC 3003
  Complete submission text file 0001193125-21-237729.txt   277869

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20210805.xsd EX-101.SCH 2914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20210805_lab.xml EX-101.LAB 18137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20210805_pre.xml EX-101.PRE 11422
7 EXTRACTED XBRL INSTANCE DOCUMENT d212533d8k_htm.xml XML 3369
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 211148435
SIC: 2834 Pharmaceutical Preparations